Diffuse Parenchymal Lung Disease
10 cases on [genuine one-line description of what this topic's real clinical territory covers] — choose a case below to open its full multi-voice debate.
A retired surveyor newly diagnosed with IPF has three real antifibrotic options for the first time — the disagreement isn't whether to treat, but which of a newly approved drug and two long-established ones actually fits him.
A patient with unnamed autoimmune-feature lung disease has real, physiologic decline but no failed treatment behind her — the disagreement is over what a diagnostic criterion written around a treatment trial actually requires when no treatment was ever tried.
A retired ironworker's new lung disease sits between a randomized trial that found benefit and a 2025 real-world study that found the opposite — the disagreement is about which kind of evidence to trust, not which drug exists.
A newly diagnosed scleroderma patient's rising skin score and elevated inflammatory markers match a landmark trial's own inclusion criteria almost exactly — the disagreement is whether that match should override the broader, older standard of care.
A physical therapist's new, rapidly worsening antisynthetase-syndrome lung disease sits between two named treatment traditions that a purpose-built trial has never finished comparing.
An HVAC technician's slow decline from pulmonary sarcoidosis has finally crossed into treatment territory the same year he and his wife started trying to conceive — the printed advice on the standard steroid-sparing agent runs against that plan while the outcome data behind it do not.
Two decades into pulmonary sarcoidosis, a dedicated gardener's disease has stopped showing signs of active inflammation but keeps declining anyway — the disagreement is between two options neither of which is actually proven for her.
A widow can't fully give up the homing pigeons her late husband raised, and her chronic hypersensitivity pneumonitis keeps worsening despite partial avoidance — the disagreement is whether immunosuppression actually helps a disease this far along.
A man's known IPF has acutely worsened, and the same guideline recommending steroids as the only real option also recommends against the immunosuppression that made his underlying disease worse — the disagreement is about what a weak recommendation actually licenses.
A woman has taken a reflux drug for three years for a diagnosis she has never actually had — the disagreement is whether the guideline that once recommended it, then reversed itself, is reason enough to stop.